The optimal male health diet and dietary supplement program

Urologic Clinics of North America

Volumn 39, Issue 1, 2012, Pages 89-107

  Moyad, Mark A ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b EISENHOWER MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Diet; Dietary supplements; Men

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CHOLESTEROL; FINASTERIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SELENIUM; TRIACYLGLYCEROL; ZINC;

ALCOHOL WITHDRAWAL; ANTHROPOMETRY; ANTIGEN DETECTION; BLOOD ANALYSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BODY MASS; CALORIC RESTRICTION; CANCER SCREENING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; DEVELOPED COUNTRY; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY FIBER; FEEDING BEHAVIOR; FRUIT; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LOW FAT DIET; MALE; MEDICAL RESEARCH; MEN'S HEALTH; MORTALITY; MOTIVATION; NUTRITIONAL COUNSELING; NUTRITIONAL REQUIREMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; TREATMENT OUTCOME; VEGETABLE; VITAMIN SUPPLEMENTATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIET; DIETARY SUPPLEMENTS; GUIDELINES AS TOPIC; HUMANS; HYPERTENSION; LIFE STYLE; MALE; MEN'S HEALTH; MIDDLE AGED; OBESITY; PROGRAM EVALUATION; UNITED STATES;

EID: 82455194898     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.09.006     Document Type: Review

References (163)

1. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
2. Bonow R.O., Smaha L.A., Smith S.C., et al. The international burden of cardiovascular disease: responding to the emerging epidemic. Circulation 2002, 106:1602-1605.
3. World Heart Federation web site. Available at: Accessed March 20, 2010. http://www.world-heart-federation.org.
4. Eyre H., Kahn R., Robertson R.M., et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 2004, 109:3244-3255.
5. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
6. Scardino P.T. The prevention of prostate cancer-the dilemma continues. N Engl J Med 2003, 349:297-299.
7. Reynolds T. Prostate cancer prevention trial yields positive results, but with a few cautions. J Natl Cancer Inst 2003, 95:1030-1031.
8. Kaplan S.A., Roehrborn C.G., Meehan A.G., et al. PCPT: evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009, 73:935-939.
9. Lippman S.M., Klein E.A., Goodman P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39-51.
10. Nash I.S., Mosca L., Blumenthal R.S., et al. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association National Survey. Arch Intern Med 2003, 163:1597-1600.
11. Hickey A., O'Hanlon A., McGee H., et al. Stroke awareness in the general population: knowledge of stroke risk factors and warning signs in older adults. BMC Geriatr 2009, 9:35.
12. The Expert Panel Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2498.
13. Grundy S.M., Cleeman J.I., Marz N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110:227-239.
14. Ketchandji M., Kuo Y.F., Shahinian V.B., et al. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 2009, 57:24-30.
15. Centers for Disease Control and Prevention (CDC) Prevalence of abnormal lipid levels among youths-United States, 1999-2006. MMWR Morb Mortal Wkly Rep 2010, 59:29-33.
16. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
17. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
18. Chang S.T., Chu C.M., Hsu J.T., et al. Independent determinants of coronary artery disease in erectile dysfunction patients. J Sex Med 2010, 7(4 Pt 1):1478-1487.
19. Kraus W.E., Houmard J.A., Duscha B.D., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347:1483-1492.
20. Hammarsten J., Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001, 39:151-158.
21. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
22. Whelton S.P., Chin A., Xin X., et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
23. Ponholzer A., Temmi C., Mock K., et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005, 47:80-85.
24. 2max and vitality in older workers: a cross-sectional study. BMC Public Health 2010, 10:684.
25. Blair S.N., Morris J.N. Healthy hearts-and the universal benefits of being physically active: physical activity and health. Ann Epidemiol 2009, 19:253-256.
26. Moyad M.A. Current methods used for defining, measuring, and treating obesity. Semin Urol Oncol 2001, 19:247-256.
27. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
28. Shike M., Latkany L., Riedel E., et al. Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. J Clin Oncol 2002, 20:3592-3598.
29. Pischon T., Boeing H., Hoffmann K., et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008, 359:2105-2120.
30. Jacobs E.J., Newton C.C., Wang Y., et al. Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med 2010, 170:1293-1301.
31. Zhu S., Heymsfield S.B., Toyoshima H., et al. Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors. Am J Clin Nutr 2005, 81:409-415.
32. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA 2005, 293:455-462.
33. Moyad M.A. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol 2001, 19:270-279.
34. Riedner C.E., Rhoden E.L., Ribeiro E.P., et al. Central obesity is an independent predictor of erectile dysfunction in older men. J Urol 2006, 176:1519-1523.
35. Bacon C.G., Mittleman M.A., Kawachi I., et al. Sexual function in men older than 50 years of age: results from the Health Professionals Follow-up Study. Ann Intern Med 2003, 139:161-168.
36. Walczak M.K., Lokhandwala N., Hodge M.B., et al. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002, 5:19-24.
37. Khoo J., Piantadosi C., Worthley S., et al. Effects of low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes 2010, 34:1396-1403.
38. Giovannucci E.L., Liu Y., Leitzmann M.F., et al. A prospective study of physical activity and incident and fatal prostate cancer. Arch Intern Med 2005, 165:1005-1010.
39. Tanasescu M., Leitzmann M.F., Rimm E.B., et al. Exercise type and intensity in relation to coronary heart disease in men. JAMA 2002, 288:1994-2000.
40. Poehlman E.T., Melby C. Resistance training and energy balance. Int J Sport Nutr 1998, 8:143-159.
41. Braith R.W., Stewart K.J. Resistance exercise training: its role in the prevention of cardiovascular disease. Circulation 2006, 113:2642-2650.
42. Hurley B.F., Roth S.M. Strength training in the elderly. Sports Med 2000, 30:249-268.
43. Platz E.A., Kawachi I., Rimm E.B., et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 1998, 158:2349-2356.
44. Blake H., Mo P., Malik S., et al. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil 2009, 23:873-887.
45. Deslandes A., Moraes H., Ferreira C., et al. Exercise and mental health: many reasons to move. Neuropsychobiology 2009, 59:191-198.
46. Blumenthal J.A., Babyak M.A., Moore K.A., et al. Effects of exercise training on older patients with major depression. Arch Intern Med 1999, 159:2349-2356.
47. Babyak M., Blumenthal J.A., Herman S., et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000, 62:633-638.
48. Moyad M.A. Dr Moyad's no bogus science health advice 2009, Ann Arbor Media Group, Ann Arbor (MI).
49. Yu J.N., Cunningham J.A., Rosenberg Thouin S., et al. Hyperlipidemia. Prim Care 2000, 27:541-587.
50. Ornish D., Weidner G., Fair W.R., et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005, 174:1065-1069.
51. Siri-Tarino P.W., Sun Q., Hu F.B., et al. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr 2010, 91:535-546.
52. Yamagishi K., Iso H., Yatsuya H., et al. Dietary intake of saturated fatty acids and mortality from cardiovascular disease in Japanese: the Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC) Study. Am J Clin Nutr 2010, 92:759-765.
53. Mozaffarian D., Micha R., Wallace S. Effects of coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010, 7:e1000252.
54. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999, 91:317-331.
55. Moyad M.A. The ABCs of nutrition and supplements for prostate cancer 2000, JW Edwards Publishers, Ann Arbor (MI).
56. Available at: Accessed October 25, 2010. http://www.usda.gov.
57. Cohen J.H., Kristal A.R., Stanford J.L. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000, 92:61-68.
58. Kristal A.R., Lampe J.W. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer 2002, 42:1-9.
59. Hsing A.W., Chokkalingam A.P., Gao Y.T., et al. Allium vegetables and risk of prostate cancer: a population-based study. J Natl Cancer Inst 2002, 94:1648-1651.
60. Walker C., Reamy B.V. Diets for cardiovascular disease prevention: what is the evidence?. Am Fam Physician 2009, 79:571-578.
61. Boffetta P., Couto E., Wichmann J., et al. Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2010, 102:1-9.
62. Pantuck A.J., Leppert J.T., Zomorodian N., et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006, 12(13):4018-4026.
63. Forest C.P., Padma-Nathan H., Liker H.R. Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind, cross-over study. Int J Impot Res 2007, 19:564-567.
64. Moyad M.A. Promoting wellness for prostate cancer patients 2010, Ann Arbor Media Group, Ann Arbor (MI). 3rd edition.
65. Uno T., Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006, 1:157-161.
66. Komperda K.E. Potential interaction between pomegranate juice and warfarin. Pharmacotherapy 2009, 29:1002-1006.
67. Van Horn L. Fiber, lipids, and coronary heart disease. Nutrition Committee advisory. Circulation 1997, 95:2701-2704.
68. Brown L., Rosner B., Willett W.W., et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999, 69:30-42.
69. Pereira M.A., O'Reilly E., Augustsson K., et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med 2004, 164:370-376.
70. Pietinen P., Rimm E.B., Korhonen P., et al. Intake of dietary fiber and risk of coronary heart disease in a cohort of Finnish men: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Circulation 1996, 94:2720-2727.
71. Rimm E.B., Ascherio A., Giovannucci E., et al. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA 1996, 275:447-451.
72. Moreyra A.E., Wilson A.C., Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med 2005, 165:1161-1166.
73. Streppel M.T., Arends L.R., van't Veer P., et al. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005, 165:150-156.
74. Marlett J.A., McBurney M.I., Slavin J.L., et al. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc 2002, 102:993-1000.
75. Pan A., Yu D., Demark-Wahnefried W., et al. Meta-analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr 2009, 90:288-297.
76. Demark-Wahnefried W., Price D.T., Polascik T.J., et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 2001, 58:47-52.
77. Demark-Wahnefried W., Robertson C.N., Walther P.J., et al. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004, 63:900-904.
78. Demark-Wahnefried W., Polascik T.J., George S.L., et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008, 17:3577-3587.
79. Zhang W., Wang X., Liu Y., et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food 2008, 11:207-214.
80. Anderson J.W., Baird P., Davis R.H., et al. Health benefits of dietary fiber. Nutr Rev 2009, 67:188-205.
81. Morris M.C., Evans D.A., Bienias J.L., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003, 60:940-946.
82. Bucher H.C., Hengstler P., Schindler C., et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002, 112:298-304.
83. Kris-Etherton P.M., Harris W.S., Appel L.J., et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
84. Harris W.S. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65(Suppl 5):1645S-1654S.
85. Morris M.C., Sacks F., Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993, 88:523-533.
86. Mori T.A., Beilin L.J., Burke V., et al. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997, 17:279-286.
87. Christensen J.H., Korup E., Aaroe J., et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997, 79:1670-1673.
88. Leaf A., Kang J.X., Xiao Y.F., et al. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003, 107:2646-2652.
89. Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002, 346:1113-1118.
90. Kromhout D. Fish consumption and sudden cardiac death. JAMA 1998, 279:65-66.
91. Moyad M.A. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: Part I. Urol Oncol 2005, 23:28-35.
92. Moyad M.A. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part II. Urol Oncol 2005, 23:36-48.
93. Augustsson K., Michaud D.S., Rimm E.B., et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:64-67.
94. Yang Y.J., Lee S.H., Hong S.J., et al. Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin Biochem 1999, 32:405-409.
95. Szymanski K.M., Wheeler D.C., Mucci L.A. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 2010, 92:1223-1233.
96. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989, 2:757-761.
97. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results from the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
98. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden cardiac death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903.
99. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
100. Guallar E., Sanz-Gallardo M.I., van't Veer P., et al. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 2002, 347:1747-1754.
101. Yoshizawa K., Rimm E.B., Morris J.J., et al. Mercury and the risk of coronary heart disease in men. N Engl J Med 2002, 347:1755-1760.
102. Weil M., Bressler J., Parsons P., et al. Blood mercury levels and neurobehavioral function. JAMA 2005, 293:1875-1882.
103. DeRouen T.A., Martin M.D., Leroux B.G., et al. Neurobehavioral effects of dental amalgam in children: a randomized clinical trial. JAMA 2006, 295:1784-1792.
104. Kris-Etherton P.M., Harris W.S., Appel L.J., et al. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003, 23:151-152.
105. Albert C.M., Gaziano J.M., Willett W.C., et al. Nut consumption and decreased risk of sudden cardiac death in the physicians' health study. Arch Intern Med 2002, 162:1382-1387.
106. Ellsworth J.L., Kushi L.H., Folsom A.R. Frequent nut intake and risk of death from coronary heart disease and all causes in postmenopausal women: the Iowa Women's Health Study. Nutr Metab Cardiovasc Dis 2001, 11:372-377.
107. Hu F.B., Willett W.C. Optimal diets for prevention of coronary heart disease. JAMA 2002, 288:2569-2578.
108. Hu F.B., Stampfer M.J., Manson J.E., et al. Frequent nut consumption and risk of coronary heart disease: prospective cohort study. BMJ 1998, 317:1341-1345.
109. Fraser G.E., Shavlik D.J. Risk factors for all-cause and coronary heart disease mortality in the oldest-old: the Adventist Health Study. Arch Intern Med 1997, 157:2249-2258.
110. Fraser G.E., Sabate J., Beeson W.L., et al. A possible protective effect of nut consumption on risk of coronary heart disease: the Adventist Health Study. Arch Intern Med 1992, 152:1416-1424.
111. Sabate J., Wien M. Nuts, blood lipids and cardiovascular disease. Asia Pac J Clin Nutr 2010, 19:131-136.
112. Casas-Agustench P., Bullo M., Salas-Salvado J. Nuts, inflammation and insulin resistance. Asia Pac J Clin Nutr 2010, 19:124-130.
113. Bjerregaard L.J., Joensen A.M., Dethlefsen C., et al. Fish intake and acute coronary syndrome. Eur Heart J 2010, 31:29-34.
114. O'Keefe J.H., Carter M.D., Lavie C.J. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc 2009, 84:741-757.
115. Esposito K., Giugliano F., Di Palo C., et al. Effect of lifestyle changes on erectile dysfunction in obese men. JAMA 2004, 291(24):2978-2984.
116. Giugliano D., Giugliano F., Esposito K. Sexual dysfunction and the Mediterranean diet. Public Health Nutr 2006, 9:1118-1120.
117. Critchley J.A., Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003, 290:86-97.
118. Plaskon L.A., Penson D.F., Vaughan T.L., et al. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003, 12:604-609.
119. Roberts W.W., Platz E.A., Walsh P.C. Association of cigarette smoking with extraprostatic prostate cancer in young men. J Urol 2003, 169:512-516.
120. Rodriguez C., Tatham L.M., Thun M.J., et al. Smoking and fatal prostate cancer in a large cohort of adult men. Am J Epidemiol 1997, 145:466-475.
121. Horasanli K., Boylu U., Kendirci M., et al. Do lifestyle changes work for improving erectile function?. Asian J Androl 2008, 10:28-35.
122. Mukamal K.J., Conigrave K.M., Mittleman M.A., et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003, 348:109-118.
123. Platz E.A., Willet W.C., Colditz G.A., et al. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 2000, 11:579-588.
124. Trichopoulou A., Costacou T., Bamia C., et al. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003, 348:2599-2608.
125. Mitrou P.N., Kipnis V., Thiebaut A.C., et al. Mediterranean dietary pattern and prediction of all-cause mortality in a U.S. population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 2007, 167:2461-2468.
126. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
127. Joshi P., Islam S., Pais P., et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007, 297:286-294.
128. Wilcox B.J., He Q., Chen R., et al. Midlife risk factors and healthy survival in men. JAMA 2006, 296:2343-2350.
129. Yates L.B., Djousse L., Kurth T., et al. Exceptional longevity in men: modifiable factors associated with survival and function to age 90 years. Arch Intern Med 2008, 168:284-290.
130. Terry D.F., Pencina M.J., Vasan R.S., et al. Cardiovascular risk factors predictive for survival and morbidity-free survival in the oldest-old Framingham Heart Study participants. J Am Geriatr Soc 2005, 53:1944-1950.
131. Rock C.L. Multivitamin-multimineral supplements: who uses them?. Am J Clin Nutr 2007, 85(Suppl):277S-279S.
132. Barqawi A., Gamito E., O'Donnell C., et al. Herbal and vitamin supplement use in a prostate cancer screening population. Urology 2004, 63:288-292.
133. Kristal A.R., Arnold K.B., Schenk J.M., et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008, 167:925-934.
134. Muntwyler J., Hennekens C.H., Manson J.E., et al. Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality. Arch Intern Med 2002, 162:1472-1476.
135. Giovannucci E., Chan A.T. Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol 2010, 28:4081-4085.
136. Lawson K.A., Wright M.E., Subar A., et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 2007, 99:754-764.
137. Stevens V.L., McCullough M.L., Diver W.R., et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005, 16:643-650.
138. Neuhouser M.L., Barnett M.J., Kristal A.R., et al. Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2009, 18:2202-2206.
139. Larsson S.C., Akesson A., Bergkvist L., et al. Multivitamin use and breast cancer incidence in a prospective cohort of Swedish women. Am J Clin Nutr 2010, 91:1268-1272.
140. Berube S., Diorio C., Brisson J. Multivitamin-multimineral supplement use and mammographic breast density. Am J Clin Nutr 2008, 87:1400-1404.
141. Clarke R., Halsey J., Lewington S., et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Arch Intern Med 2010, 170:1622-1631.
142. Collin S.M., Metcalfe C., Refsum H., et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010, 19:1632-1642.
143. Ng K., Meyerhardt J.A., Chan J.A., et al. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2010, 28:4354-4363.
144. Hercberg S., Galan P., Preziosi P., et al. The SU.VI. MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004, 164:2335-2342.
145. Meyer F., Galan P., Douville P., et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI. MAX trial. Int J Cancer 2005, 116:182-186.
146. Christen W.G., Gaziano J.M., Hennekens C.H. Design of Physicians' Health Study II-a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000, 10:125-134.
147. Barnett C.M., Nielson C.M., Shannon J., et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 2010, 21:1297-1303.
148. Michaelsson K., Baron J.A., Snellman G., et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 2010, 92:841-848.
149. Sanders K.M., Stuart A.L., Williamson E.J., et al. Annual high-dose oral vitamin D and falls and fractures in older women. JAMA 2010, 303:1815-1822.
150. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
151. Zerwekh J.E. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008, 87(Suppl):1087S-1091S.
152. Isenor J.E., Ensom M.H. Is there a role for therapeutic drug monitoring of vitamin D level as a surrogate marker for fracture risk. Pharmacotherapy 2010, 30:254-264.
153. Moyad M.A. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I. Urol Oncol 2004, 22:466-471.
154. Moyad M.A. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. Urol Oncol 2004, 22:472-477.
155. Moyad M.A. Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I. Curr Opin Urol 2005, 15:1-6.
156. Moyad M.A. Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part II. Curr Opin Urol 2005, 15:7-12.
157. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
158. Everett B.M., Glynn R.J., MacFadyen J.G., et al. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010, 121:143-150.
159. Platz E.A., Till C., Goodman P.J., et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2009, 18:2807-2813.
160. Murtola T.J., Visakorpi T., Lahtela J., et al. Statins and prostate cancer prevention: where we are now and future directions. Nat Clin Pract Urol 2008, 5:376-387.
161. St Sauver J.L., Jacobsen S.J., Jacobson D.J., et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 2011, 107(3):443-450.
162. Dadkhah F., Safarinejad M.R., Asgari M.A., et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction and not initially responsive to sildenafil. Int J Impot Res 2010, 22:51-60.
163. Katz M.S., Carroll P.R., Cowan J.E., et al. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010, 106:627-632.